BioCentury
ARTICLE | Clinical News

GS-4774: Phase II data

June 1, 2015 7:00 AM UTC

Top-line data from the open-label, U.S. and New Zealand Phase II GS-US-330-0101 trial in 178 virally suppressed patients with chronic HBV infection showed that 40 yeast units of subcutaneous GS-4774 o...